Lytenava (bevacizumab gamma), is the first licensed version of Avastin for wet age-related macular degeneration. The treatment was approved by the National Institute for Health and Care Excellence (NICE) for use in the NHS last year.
In this webinar, professor Andrew Lotery breaks down what this new treatment means for you. He’ll also discuss how Lytenava compares to existing treatments, such as Eylea and Lucentis, its potential benefits, and what this approval means for NHS patients.